Loginova S Ya, Shсhukina V N, Savenko S V, Borisevich S V
FSBI «Central Scientific Research Institute No. 48» of the Ministry of Defense of Russia.
Vopr Virusol. 2021 May 15;66(2):123-128. doi: 10.36233/0507-4088-13.
The pandemic spread of a new coronavirus infection, COVID-19, has caused a global emergency and attracted the attention of public health professionals and the population of all countries. A significant increase in the number of new cases of SARS-CoV-2 infection demonstrates the urgency of finding drugs effective against this pathogen.The aim of this work was to evaluate the in vitro antiviral efficacy of human recombinant alpha-2b interferon (IFN-α2b) against SARS-CoV-2 virus.
The experiments had been carried out on Vero Cl008, the continuous line of African green monkey (Chlorocebus sabaeus) kidney cells. The effectiveness of the drugs was assessed by the suppression of viral reproduction in vitro. The biological activity was determined using titration of a virus-containing suspension in a Vero Cl008 cell culture by the formation of negative colonies.
The antiviral efficacy of the IFN-α2b-based medications, which have a high safety profile and proven efficacy in the prevention and treatment of influenza and acute respiratory viral infections (ARVI), has been studied against the new pandemic SARS-CoV-2 virus in vitro experiments in Vero C1008 cell culture. IFN-α2b effectively inhibits the reproduction of the virus when applied both 24 hrs before and 2 hrs after infection. In the IFN-α2b concentration range 102-106 IU/ml a complete suppression of the reproduction of the SARS-CoV-2 virus had been demonstrated.
IFN-α2b demonstrated in vitro high antiviral activity against SARS-CoV-2. In addition, the substance has a high chemotherapeutic index (>1000).
Medications for intranasal use based on IFN-α2b have high antiviral activity and are promising drugs for in vivo study in terms of prevention and treatment of COVID-19.
新型冠状病毒感染COVID-19的大流行引发了全球紧急情况，吸引了各国公共卫生专业人员和民众的关注。严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染新病例数量的显著增加表明，寻找有效对抗这种病原体的药物迫在眉睫。本研究的目的是评估重组人α-2b干扰素（IFN-α2b）对SARS-CoV-2病毒的体外抗病毒疗效。
实验在非洲绿猴（绿猴）肾细胞连续系Vero Cl008上进行。通过体外抑制病毒复制来评估药物的有效性。通过在Vero Cl008细胞培养物中对含病毒悬液进行滴定，形成阴性菌落来测定生物活性。
在Vero C1008细胞培养的体外实验中，研究了基于IFN-α2b的药物的抗病毒疗效，这些药物具有高安全性，且在预防和治疗流感及急性呼吸道病毒感染（ARVI）方面具有已证实的疗效。IFN-α2b在感染前24小时和感染后2小时应用时均能有效抑制病毒复制。在102-106 IU/ml的IFN-α2b浓度范围内，已证明能完全抑制SARS-CoV-2病毒的复制。
IFN-α2b在体外对SARS-CoV-2表现出高抗病毒活性。此外，该物质具有高化疗指数（>1000）。
基于IFN-α2b的鼻内用药具有高抗病毒活性，在预防和治疗COVID-19方面是有前景的体内研究药物。
